Carlsmed (CARL) reported a Q2 loss late Thursday of $1.47 per diluted share, narrower than a loss of $1.55 a year earlier.
Three analysts polled by FactSet expected a loss of $0.71.
Revenue for the quarter ended June 30 rose to $12.1 million from $6.1 million a year earlier.
Three analysts surveyed by FactSet expected $12.0 million.
The company said it expects 2025 revenue of $45.5 million to $47.5 million, representing growth of 67% to 75% over 2024. Analysts polled by FactSet expect $45.7 million.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.